Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WIP-2401
- Development stage
- Preclinical
- Lead developer
- WhanIn Pharm
- Modality
- Small Molecules
01
Overview
**WIP-2401** is a Whan In Pharmaceutical investigational modified-drug product for depression. Whan In's public pipeline identifies the program as WIP-2401 and lists depression as its indication. The specific active ingredient, formulation technology, molecular target, and mechanism of action have not been publicly disclosed by the sponsor. Public Korean reporting describes a Phase 1 pharmacokinetic and safety study involving WIP-2401 and the distinct comparator or related product WIP-2401-R, and later reporting indicates that Whan In submitted a marketing-authorization application for WIP-2401. ([whanin.com](https://www.whanin.com/_commonBase/content.php?co_id=pipeline_en))
- Other names
- WIP 2401WIP2401WIP-2401
Beyond the preview
Go deeper on WIP-2401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WIP-2401.